Abstract:Fanconi anemia (FA) cells are characterized by genomic instability, which places FA patients at risk for malignancies such as leukemia and oropharyngeal/urogenital cancers. The risk of development of leukemia is theoretically eliminated after hematopoietic cell transplantation (HCT). Mixed chimerism (MC) in FA patients might have a unique implication because the persistent existence of FA cells might give rise to a malignant clone. We have studied a large population of FA patients who underwent allogeneic HCT at our institution and report here the outcome according to chimerism status. Patients with FA who had evidence of progressive bone marrow failure and were blood products-transfusion dependent (packed red blood cells, platelets, or both) were included in the study. Those who had myelodysplasia (MDS) or an abnormal clone or evidence of leukemia were excluded. All but 3 patients had normal renal and cardiac function at the time of transplantation. In total, 160 patients with FA underwent allogeneic HCT at our center from January 1995 to December 2017; mean age at HCT was 8.4. Chimerism data at last follow-up visit were available on 97 patients who are the subjects of this analysis (no day +100 chimerism data on one of them). On day +100, 46 patients (47.9%) had full chimerism (FC) and 50 (52.1%) had MC, whereas at last follow-up 50 (51.5%) exhibited FC and the remaining 47 (48.5%) had MC. Cumulative incidence of all grades acute graft-versus-host disease (GVHD) was 13.4% and that of grade III to IV GVHD was 4.1%. Chronic GVHD was seen in eight (8.0%) patients. Incidence of severe acute GVHD (grade ≥ III) and that of chronic GVHD were not significantly associated with FC or MC measured at day +100 (P values = .347 and .254, respectively), nor at the last follow-up. Graft failure occurred in 2 patients; both from the MC at day +100 group. No graft failures occurred in the FC at day +100 group (P value = 1.00). At a median follow-up of 83.8 months (95% confidence interval, 51.0-116.6; range, 19.3-181.1 months) the cumulative probability of overall survival (OS) at 5 years was 95.7% ± 2.1%. Mean follow-up time in our cohort was 90.7 months. Five-year overall survival was not significantly associated with FC or MC evaluated at day +100 (95.7% ± 3.0% versus 95.6% ± 3.1%, P value = .908) nor at the last follow-up (96.0% ± 2.8% versus 95.4% ± 3.2%, P value = .925). No patient in either group developed MDS/leukemia during the follow-up period. We conclude that mixed chimerism in patients with FA appears to have no adverse effect on outcome in our follow-up period. A longer follow-up period is needed, however, to confirm the validity of this statement.

Diagnosis and Treatment of Fanconi Anemia and Literature Review

Longitudinal clinical manifestations of Fanconi anemia: A systematized review

[Association between clinical outcome and gene mutation in children with Fanconi anemia].

Phenotypic and Genotypic Correlation Evaluation of 148 Pediatric Patients with Fanconi Anemia in a Chinese Rare Disease Cohort.

Identification of Immune Infiltration, Differentially Expressed Genes, and Signaling Pathways in Fanconi Anemia Based on Bioinformatics Analysis

Comprehensive Analysis on Phenotype and Genetic Basis of Chinese Fanconi Anemia Patients: Dismal Outcomes Call for Nationwide Studies

Functional analysis of Fanconi anemia mutations in China.

Clinical and genetic features of Fanconi anemia associated with a variant of FANCA gene: Case report and literature review

Unmanipulated Haploidentical Haematopoietic Cell Transplantation with Radiation-Free Conditioning in Fanconi Anaemia: A Retrospective Analysis from the Chinese Blood and Marrow Transplantation Registry Group

In Utero Hematopoietic Stem Cell Transplant for Fanconi Anemia

Stem Cell Genetic Therapy for Fanconi Anemia - A New Hope

Does Mixed Chimerism After Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients With Fanconi Anemia Impact on Outcome?

Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review

Modelling Fanconi Anemia Pathogenesis and Therapeutics Using Integration-Free Patient-Derived Ipscs.

A Crosstalk Between Inflammation and Oxidative Stress

Novel Variations of FANCA Gene Provokes Fanconi Anemia: Molecular Diagnosis in a Special Chinese Family

Genetic analysis of a Fanconi anemia case revealed the presence of FANCF mutation (exon 1;469>C-T) with implications to develop acute myeloid leukemia

Diagnosis and Treatment for Squamous Cell Carcinoma of the Oral Tongue in a Patient with Fanconi Anemia

Mutation Spectrum, Expression Profiling, and Prognosis Evaluation of Fanconi Anemia Signaling Pathway Genes for 4259 Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Role of the mesenchymal stromal cells in bone marrow failure of Fanconi Anemia patients

Clinical and Genetic Spectrum of Fanconi Anaemia in Australia and New Zealand.